We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Growth of In-Situ Hybridization Testing Exceeds Other Technologies

By LabMedica International staff writers
Posted on 26 Apr 2010
In situ hybridization tests (ISH), which are probes for specific DNA sequences performed on portions of tumor tissue, have become one of the fastest growing market segments in laboratory medicine, showing 8% sales growth per year, according to a recent market report. More...


With new enhancements the technology will continue to drive revenues for Abbott Laboratories (Abbott Park, IL, USA), Genzyme (Cambridge, MA, USA), Nitrogen (Carlsbad, CA, USA), and a host of other test makers, according to a report from healthcare market research publisher Kalorama Information (New York, NY, USA). The report noted that ISH has performed better than other technologies that were predicted to dominate the industry.

"ISH is carving out a growing market share because of its usefulness for a variety of cancer markers including ER [estrogen receptor], PSA [prostate-specific antigen], EGFR [epidermal growth factor receptor], and Her-2 [human epidermal growth factor receptor 2],” said Shara Rosen, senior diagnostic analyst for Kalorama Information. "It has outperformed expectations made for it in the last decade and shown more growth so far than other celebrated areas such as microarrays and DNA assays.”

The world market for all ISH (silver, chromomeric, or fluorescent) is estimated by Kalorama Information to be US$670 million in 2009. Vendor sales are comprised mostly of individual antibodies or probes and instrumentation to automate the staining and reading of slides, along with digital imaging systems and data analysis software in high-end systems. It is these systems, which offer automated sample preparation and digital analysis instrumentation that Kalorama Information believes will continue to put ISH in a leadership position, allowing for same-day biopsy results and better patient care.

"The technology is moving from manual and operator-read to automated and digitally interpreted,” said Ms. Rosen. "ISH testing used to be qualitative and inherently subjective; resulting in significant deficiencies in the interpretation of test results, but automation has made it more relevant.”

The new automation has also allowed some movement of histology from hospital and reference laboratories to large physician practices in the United States. Digital imaging can convert entire microscope slides into high-resolution digital slides. Therefore, digitized images of an entire slide can be analyzed, stored, and remotely viewed on computer monitors located anywhere. This digital capability sets the stage for pathology telemedicine and small bench top systems for small labs and physician office laboratories as well as labs in rural areas, according to Kalorama.

Related Links:

Kalorama Information



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.